HC Wainwright Lowers X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $1.50

X4 Pharmaceuticals (NASDAQ:XFOR) had its target price dropped by stock analysts at HC Wainwright from $5.00 to $1.50 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 271.75% from the company’s current price.

Separately, Stifel Nicolaus lowered their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ:XFOR opened at $0.40 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.07 and a quick ratio of 6.04. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60. The firm has a market capitalization of $67.99 million, a PE ratio of -4.42 and a beta of 0.39. The business’s 50 day moving average price is $0.59 and its 200-day moving average price is $0.75.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $3.43 million for the quarter. As a group, equities research analysts expect that X4 Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $126,854.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This represents a 13.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 580,800 shares of company stock worth $321,447 in the last three months. 1.62% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth $30,000. SG Americas Securities LLC purchased a new position in X4 Pharmaceuticals during the third quarter worth about $37,000. Price T Rowe Associates Inc. MD increased its position in shares of X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after acquiring an additional 12,514 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of X4 Pharmaceuticals during the second quarter valued at about $65,000. Finally, Rhumbline Advisers raised its stake in shares of X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.